TD Cowen says Spyre Therapeutics (SYRE)’ webcast “strengthened our confidence in an already great dataset” for SPY001, but adds that both management and the firm remains bullish on combos, where a “super-vedo” backbone positions SPY120 and SPY130 to deliver best-in-indication efficacy that “could enable IBD dominance.” The firm has a Buy rating on Spyre shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $106 from $49 at Leerink
- Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
- Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka
- Spyre Therapeutics price target raised to $98 from $70 at BTIG
- Spyre Therapeutics price target raised to $85 from $47 at Jefferies